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Adding fuel to the flames? It is time to leave HCAPHealthcare-associated pneumonia (HCAP) has been intro-
duced as an entity in the ATS/IDSA guidelines update from
2005.1 The main reason behind was the notion that chronic
healthcare contacts are a reasonable surrogate for an
increased risk of multidrug-resistant (MDR) pathogens
which might not be covered following guidelines for
community-acquired pneumonia (CAP), thereby accounting
for the high mortality observed in these patients. As
a consequence, patients meeting criteria for HCAP should
receive much broader empiric antimicrobial treatment.
At that time, data supporting this concept were scarce.2
Several studies have been published in the following in
order to investigate the validity of this approach. Although
someauthors claimed to have added evidence to the concept
of HCAP,3e7 a critical appraisal of the data raised serious
concerns about the interpretation of these data.8,9 Themain
criticisms relate to a) the heterogeneous definitions of HCAP
across studies, b) the use of routine microbiological data,
some without indicating methodology of work-up, c) the
usually low incidence of MDR pathogens, at least if immu-
nosuppression is excluded from theHCAP concept (aswas the
case in the original definition), d) the lack of association
between MDR as etiology and observed excess mortality, as
well as the failure of HCAP guideline concordant treatment
to reducemortality10,11 and e) the consequences of theHCAP
concept in terms of excessive selection pressure by applying
broader empiric antimicrobial treatment topatientsmeeting
its criteria. In fact, several studies from Europe do not
support the HCAP concept.12e14
Most of these concernsprove truewhenanalyzing thedata
provided by Park et al. in this issue of RespiratoryMedicine.15
In fact, although the incidence of MDR pathogens was very
high, not all HCAP criteria were good predictors for the
presence of MDR pathogens, implying an excessive over-
treatment in many patients meeting HCAP criteria. Although
the microbiological work-up seemed sound, the high inci-
dence of MDR pathogens cannot be related to HCAP alone
since the incidence of MDR was also excessively high in CAP;
e.g., an incidence of 15% Klebsiella pneumoniae and 13%
Pseudomonas aeruginosa in CAP is highly unusual and hints at
factors not elaborated in the analysis accounting for that. Of
note, 42% of HCAP patients were recently hospitalized, and0954-6111/$ - see front matter ª 2012 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2012.07.00227% were severely immunosuppressed. There was an excess
mortality in HCAP patients, however, despite a higher
number of inadequate antimicrobial treatment in patients
with MDR pathogens, this number was not different between
CAP and HCAP patients, and there was no association
between excessmortality and inadequate treatment and the
presence of MDR pathogens.
Overall, thesedataagaindonot support theHCAPconcept,
in the contrary, contribute important data against it. MDR
pathogens were significantly predicted by recent hospitali-
zation within 90 days, recent antimicrobial treatment within
30 days, and nasogastric tube feeding, but not by other HCAP
criteria. The association of nursing-home residence or
extended health care facility (and consequently nursing-
home associated pneumonia, NHAP) and MDR pathogens is
amatter of debate, but at least European data do not support
such association.16,17 Hemodialysis, wound care, chemo-
therapy in the last 30 days all also failed to be predictive.18,19
Nasogastric tube was also identified as a risk factor for P.
aeruginosa in a recent German study.20 However, nasogastric
tubes are probably a surrogate for a bedridden condition, and
manyof suchpatients suffer pneumonia as a terminal event of
a longstandingand severecomorbidity, are considered tohave
a futile prognosis and are subject to treatment restrictions.
In fact, the association of MDR with previous hospitali-
zation and antimicrobial treatment has been repeatedly
shown and is confirmed by this study.21 However, in our
view, there is no need to break up the traditional pneu-
monia triad and introduce a new entity when prior anti-
microbial treatment and previous hospitalization are
handled as indicators for the need of an approach along the
guidelines for nosocomial pneumonia.8
We do not support attempts to refine HCAP criteria as
presented earlier22e24 and also in the study by Park et al.,15
first because predictions remain poorly convincing and
second for the reason of simplicity. HCAP or similar entities
with varying definitions introduce much confusion and
probably have already caused heavy overtreatment in
routine practice. The use of HCAP means adding fuel to the
flames of worldwide increasing microbial resistance levels.
This is particularly true for most European countries with
apparently low incidences of MDR pathogens in patients.
1310 Editorialwith CAP and HCAP. On the other hand, advocating the
importance of culture-positive HCAP does not make much
sense: since culture positivity is not known at the start of
antimicrobial treatment, it does not help in selecting
antimicrobial treatment; the need to adjust treatment
after identification of a resistant pathogen is self-evident.25
Instead, we advocate to keep with the traditional
pneumonia triad, encouraging each physician caring for
pneumonia patients to search for potential risk factors for
MDR pathogens in the individual patient. Evidently,
researchers should make every effort to identify more and
better predictors for such risk.
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